Rapid and accurate eXDR screening: use Xpert Carba-R® with FecalSwab®.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 10 07 2020
revised: 15 11 2020
accepted: 20 11 2020
pubmed: 3 1 2021
medline: 17 8 2021
entrez: 2 1 2021
Statut: ppublish

Résumé

The FecalSwab® displays high performances for stool culture, but it was not assessed for carbapenemase-producing Enterobacterales (CPE) screening. We assess the performances of the Xpert Carba-R v2® with the FecalSwab®. Using a collection of 12 CPE strains, the limit of detection was assessed at 158 CFU/swab [interquartile range 93-589]. In 2019, 1540 swabs were included by 4 hospital laboratories, of which 39 (2.5%) yield an invalid result. Among the 1501 valid, 87 (5.8%) were positives by culture and PCR and 25 (1.7%) were discrepant: 7 PCR-negative culture-positive, and 18 PCR-positive culture-negative. Two PCR-positive culture-negative results involved non-Enterobacterales strains: a KPC-producing Acinetobacter baumannii and a KPC-producing Aeromonas spp. The overall percent agreement was 98.3% and the Kappa value was 0.88. FecalSwab® is an accurate sampling device for CPE screening. It allows performing all eXDR screening using a single swab, simplifying the sample collection, and improving the patient comfort. Regarding discrepant, we suggest combining a CPE screening by both culture and Xpert Carba-R v2® methods.

Identifiants

pubmed: 33387895
pii: S0732-8893(20)30656-8
doi: 10.1016/j.diagmicrobio.2020.115279
pii:
doi:

Substances chimiques

Bacterial Proteins 0
Vancomycin 6Q205EH1VU
beta-Lactamases EC 3.5.2.6
carbapenemase EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115279

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The Xpert Carba-R v2® reagents used for the assessment of the limit of detection were provided free of charge by Cepheid®.

Auteurs

Eric Farfour (E)

Service de Biologie Clinique, Hôpital Foch, Suresnes, France. Electronic address: e.farfour@hopital-foch.org.

Alexandra Lomont (A)

Service de microbiologie et hygiène hospitalière, Hôpital Franco-Musulman Avicenne, Bobigny, France.

Vincent Fihman (V)

Unité de Bactériologie-Hygiène, Département de Prévention, Diagnostic et Traitement des Infections,Hôpital Henri Mondor, Créteil, France.

Marion Lecuru (M)

Service de Biologie Clinique, Hôpital Foch, Suresnes, France.

Sophie Hüssler (S)

Unité de Bactériologie-Hygiène, Département de Prévention, Diagnostic et Traitement des Infections,Hôpital Henri Mondor, Créteil, France.

Souad Ouzani (S)

Service de Microbiologie Hygiène Hospitalière, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Jean-Ralph Zahar (JR)

Service de microbiologie et hygiène hospitalière, Hôpital Franco-Musulman Avicenne, Bobigny, France.

Laurent Dortet (L)

Service de Microbiologie Hygiène Hospitalière, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; CNR de la Résistance Aux Antibiotiques, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH